Apply to trial NCT07255963

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

This study aims to evaluate the efficacy of combining pirtobrutinib, lisaftoclax, and rituximab (PVR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy and to explore a more effective treatment strategy for this patient population.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening